Advertisement

International Journal of Clinical Pharmacy

, Volume 33, Issue 6, pp 929–933 | Cite as

Pharmacist interventions on antibiotic use in inpatients with respiratory tract infections in a Chinese hospital

  • Jian Shen
  • Qingmin Sun
  • Xianmei Zhou
  • Yu Wei
  • Yongjian Qi
  • Jiping Zhu
  • Tingting YanEmail author
Short Research Report

Abstract

Objective To evaluate the impact of pharmacist interventions on antibiotic use in inpatients with respiratory tract infections in a tertiary hospital in China. Method Two independent respiratory wards were randomized into control and intervention group. Between July 2009 and April 2010, all inpatients diagnosed with respiratory tract infections were enrolled. Pharmacist interventions were performed on the physicians in the intervention group. The total cost of hospitalization, cost of antibiotics, length of hospital stay and the scores of 6 items of inappropriate antibiotic use (including indication, choice, dosage, dosing schedule, duration and conversion) were analyzed. Results The total costs of hospitalization in the intervention group were significant lower compared to the control group ($1442.3 ± 684.9 vs. $1729.6 ± 773.7, P < 0.001), as well as the cost of antibiotics ($832.0 ± 373.0 vs. $943.9 ± 412.0, P = 0.01), and the patients required shorter length of hospital stay (14.2 ± 6.2 vs. 15.8 ± 6.0 days, P = 0.03). The scores with respect to the 6 items of inappropriate antibiotic use were all lower in the intervention group than in the control group. Conclusions Pharmacist interventions, interacted directly with the physicians at ward level, could play an important role in optimizing antibiotic use, thus lead to the reduction in patients’ length of hospital stay and health care cost.

Keywords

Antibiotic use China Pharmacist interventions Respiratory tract infections 

Notes

Acknowledgments

We thank all physicians and nurses who have participated in this study. We thank the pharmacy students for their assistance. Also we would like to thank Dr. Can Luo (Department of Pharmacy, Jiangsu Province Hospital, China) for helpful suggestions and critical reading of the manuscript.

Funding

None.

Conflicts of interest

None

References

  1. 1.
    Anderson RM. The pandemic of antibiotic resistance. Nat Med. 1999;5(2):147–9.PubMedCrossRefGoogle Scholar
  2. 2.
    John JF Jr, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis. 1997;24(3):471–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Heddini A, Cars O, Qiang S, Tomson G. Antibiotic resistance in China—a major future challenge. Lancet. 2009;373(9657):30.PubMedCrossRefGoogle Scholar
  4. 4.
    Reynolds L, McKee M. Factors influencing antibiotic prescribing in China: an exploratory analysis. Health Policy. 2009;90(1):32–6.PubMedCrossRefGoogle Scholar
  5. 5.
    von Gunten V, Reymond JP, Beney J. Clinical and economic outcomes of pharmaceutical services related to antibiotic use: a literature review. Pharm World Sci. 2007;29(3):146–63.CrossRefGoogle Scholar
  6. 6.
    Weller TMA, Jamieson CE. The expanding role of the antibiotic pharmacist. J Antimicrob Chemother. 2004;54(2):295–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Zhu M, Guo DH, Liu GY, Pei F, Wang B, Wang DX, et al. Exploration of clinical pharmacist management system and working model in China. Pharm World Sci. 2010;32(4):411–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(3):357–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Hung MN, Hsueh PR, Chang HT, Lee WS, Chou MY, Chen IS, et al. In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive care units in Taiwan: SMART 2004 programme data. Int J Antimicrob Agents. 2007;29(2):145–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10–22.PubMedCrossRefGoogle Scholar
  11. 11.
    Al-Momany NH, Al-Bakri AG, Makahleh ZM, Wazaify MM. Adherence to international antimicrobial prophylaxis guidelines in cardiac surgery: a Jordanian study demonstrates need for quality improvement. J Manag Care Pharm. 2009;15(3):262–71.PubMedGoogle Scholar
  12. 12.
    Vogel F. Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents? Drugs. 2002;62(2):309–17.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ. Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health. 2006;2:6.PubMedCrossRefGoogle Scholar
  14. 14.
    Deuster S, Roten I, Muehlebach S. Implementation of treatment guidelines to support judicious use of antibiotic therapy. J Clin Pharm Ther. 2010;35(1):71–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Jian Shen
    • 1
  • Qingmin Sun
    • 1
  • Xianmei Zhou
    • 2
  • Yu Wei
    • 2
  • Yongjian Qi
    • 2
  • Jiping Zhu
    • 2
  • Tingting Yan
    • 3
    Email author
  1. 1.Department of PharmacyAffiliated Hospital of Nanjing University of Chinese MedicineNanjingPeople’s Republic of China
  2. 2.Department of RespirationAffiliated Hospital of Nanjing University of Chinese MedicineNanjingPeople’s Republic of China
  3. 3.Nanjing University of Chinese MedicineNanjingPeople’s Republic of China

Personalised recommendations